269 related articles for article (PubMed ID: 28769798)
1. Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing.
Abdul SN; Ab Mutalib NS; Sean KS; Syafruddin SE; Ishak M; Sagap I; Mazlan L; Rose IM; Abu N; Mokhtar NM; Jamal R
Front Pharmacol; 2017; 8():465. PubMed ID: 28769798
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.
Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K
Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861
[TBL] [Abstract][Full Text] [Related]
3. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.
Wang JY; Hsieh JS; Chang MY; Huang TJ; Chen FM; Cheng TL; Alexandersen K; Huang YS; Tzou WS; Lin SR
World J Surg; 2004 Jul; 28(7):721-6. PubMed ID: 15185002
[TBL] [Abstract][Full Text] [Related]
4. Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes.
Chiang JM; Wu Chou YH; Ma SC; Chen JR
Virchows Arch; 2004 Nov; 445(5):465-71. PubMed ID: 15449054
[TBL] [Abstract][Full Text] [Related]
5. Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience.
Youssef ASE; Abdel-Fattah MA; Lotfy MM; Nassar A; Abouelhoda M; Touny AO; Hassan ZK; Mohey Eldin M; Bahnassy AA; Khaled H; Zekri ARN
Curr Issues Mol Biol; 2022 Mar; 44(3):1332-1352. PubMed ID: 35723313
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients.
Horiuchi A; Iinuma H; Akahane T; Shimada R; Watanabe T
Oncol Rep; 2012 May; 27(5):1384-92. PubMed ID: 22267128
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer.
Fukushima Y; Iinuma H; Tsukamoto M; Matsuda K; Hashiguchi Y
Oncol Rep; 2015 Feb; 33(2):573-82. PubMed ID: 25421755
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases.
Chen WS; Chen JY; Liu JM; Lin WC; King KL; Whang-Peng J; Yang WK
Int J Cancer; 1997 Aug; 74(4):470-4. PubMed ID: 9291442
[TBL] [Abstract][Full Text] [Related]
10. Prognosis in Duke's B colorectal carcinoma: the Jass classification revisited.
De Quay N; Cerottini JP; Albe X; Saraga E; Givel JC; Caplin S
Eur J Surg; 1999 Jun; 165(6):588-92. PubMed ID: 10433145
[TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of metastasis-related tumor markers in colorectal cancer].
Wan XB; Pan ZZ; Ren YK; Ding PR; Chen G; Wan DS
Ai Zheng; 2009 Sep; 28(9):950-4. PubMed ID: 19728913
[TBL] [Abstract][Full Text] [Related]
12. NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencing.
Chang PY; Chen JS; Chang NC; Chang SC; Wang MC; Tsai SH; Wen YH; Tsai WS; Chan EC; Lu JJ
Oncotarget; 2016 Jun; 7(25):37566-37580. PubMed ID: 27121310
[TBL] [Abstract][Full Text] [Related]
13. Detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR for CEA and CK20 mRNAS.
Oberg AN; Lindmark GE; Israelsson AC; Hammarström SG; Hammarström ML
Int J Cancer; 2004 Aug; 111(1):101-10. PubMed ID: 15185350
[TBL] [Abstract][Full Text] [Related]
14. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.
Arango D; Laiho P; Kokko A; Alhopuro P; Sammalkorpi H; Salovaara R; Nicorici D; Hautaniemi S; Alazzouzi H; Mecklin JP; Järvinen H; Hemminki A; Astola J; Schwartz S; Aaltonen LA
Gastroenterology; 2005 Sep; 129(3):874-84. PubMed ID: 16143127
[TBL] [Abstract][Full Text] [Related]
15. Gene expression in colorectal cancer.
Birkenkamp-Demtroder K; Christensen LL; Olesen SH; Frederiksen CM; Laiho P; Aaltonen LA; Laurberg S; Sørensen FB; Hagemann R; ØRntoft TF
Cancer Res; 2002 Aug; 62(15):4352-63. PubMed ID: 12154040
[TBL] [Abstract][Full Text] [Related]
16. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer.
Carpelan-Holmström M; Haglund C; Lundin J; Järvinen H; Roberts P
Eur J Cancer; 1996 Jun; 32A(7):1156-61. PubMed ID: 8758246
[TBL] [Abstract][Full Text] [Related]
17. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
18. Classification of Dukes' B and C colorectal cancers using expression arrays.
Frederiksen CM; Knudsen S; Laurberg S; Ørntoft TF
J Cancer Res Clin Oncol; 2003 May; 129(5):263-71. PubMed ID: 12750996
[TBL] [Abstract][Full Text] [Related]
19. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
20. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients.
Diep CB; Thorstensen L; Meling GI; Skovlund E; Rognum TO; Lothe RA
J Clin Oncol; 2003 Mar; 21(5):820-9. PubMed ID: 12610180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
